Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation

October 15, 2020
Margaret M. Faul

,
Carl L. McMillian

,
Pierre Boulas

,
Reginaldo A. Saraceno

,
Mary Devlin Capizzi

,
Maureen T. Cruz

Pharmaceutical Technology, Pharmaceutical Technology-10-15-2020, Volume 2020 eBook, Issue 3
Page Number: 60-64

The IQ Consortium marks a decade of impactful innovation of collaboration through a network of pharmaceutical companies driving change for the bio/pharmaceutical industry.

Pharmaceutical development is a long, risky, and expensive process. In this highly competitive market, pharmaceutical companies are under constant pressure to deliver innovation via new therapeutics, new technology, and improved efficiency and effectiveness (1). Precompetitive collaboration is recognized as a mechanism to enhance efficiency, mitigate risks, and share costs that can benefit industry, academia, and government agencies. For the purposes of this viewpoint, “precompetitive collaboration” may be defined as collaborations between pharmaceutical companies and third parties to produce an efficiency-enhancing advancement or refinement that will be made broadly available to the public (i.e., publication, commercialization of a new product).

Read this article in Pharmaceutical Technology's Regulatory Sourcebook October 2020 eBook.

Article Details

Pharmaceutical Technology
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 60–64

Citation

When referring to this article, please cite it as M. M. Faul et al.,Viewpoint: Precompetitive Collaboration Drives Pharma Industry Innovation," Pharmaceutical Technology Regulatory Sourcebook eBook (October 2020).